InvestorsHub Logo
Followers 94
Posts 6231
Boards Moderated 1
Alias Born 01/29/2015

Re: None

Thursday, 12/08/2016 10:21:41 AM

Thursday, December 08, 2016 10:21:41 AM

Post# of 8305
Tonix Pharmaceuticals Presented New Clinical Results from Sub-Group Analysis of Phase 2 AtEase Study in Military-Related Posttraumatic Stress Disorder (PTSD)

Here are the slides. It's too many photos to post here but it gives a good overall picture of what they are presenting:

EX-99.01 2 s104910_ex99-01.htm EX-99.01

https://www.sec.gov/Archives/edgar/data/1430306/000161577416008783/s104910_ex99-01.htm



And the words:

EX-99.3 3 s104910_ex99-03.htm EXHIBIT 99-3

https://www.sec.gov/Archives/edgar/data/1430306/000161577416008783/s104910_ex99-03.htm


Sub-Group Analysis of the Phase 2 AtEase Clinical Study Confirms TNX-102 SL’s Potential Efficacy in Combat-Related PTSD Patients Who are the Most Difficult to Treat



New Results Presented in Poster Session at the American College of Neuropsychopharmacology (ACNP) Annual Meeting



NEW YORK, Dec. 8, 2016 – Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, recently presented new results from a sub-group analysis of the data from the AtEase study, a 12-week, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL*, 5.6 mg, in military-related PTSD.



The sub-group analysis focused on those patients whose index trauma in the AtEase study was directly related to combat. Patients were enrolled in the trial with military-related PTSD, which was defined by trauma during military service and included combat trauma, but also included non-combat trauma such as sex trauma. Combat-related PTSD represented the majority of index traumas in the AtEase study (85%; N=197). The combat-related PTSD sub-group was analyzed for those with baseline scores of the Clinician Administered PTSD Scale for the Diagnostic and Statistical Manual for Mental Illness, Edition 5, or CAPS-5, at baseline of ≥ 33, as well as for the whole population with entry CAPS-5 ≥ 29. The sub-group analysis confirmed that patients with combat-related PTSD and entry CAPS-5 ≥ 33, treated with TNX-102 SL, 5.6 mg, showed improvement on total CAPS-5 severity, in addition to certain items in CAPS-5 cluster scores, such as reckless and self-destructive behavior. Functional improvement by the Sheehan Disability Scale total score, work and social items was also observed in the sub-group with CAPS-5 ≥ 33, treated with TNX-102 SL, 5.6 mg.



Gregory Sullivan, M.D., chief medical officer of Tonix, presented these findings at the 55th Annual Meeting of the American College of Neuropsychopharmacology on December 7, 2016 in Hollywood, FL, in a poster session. The poster showcasing this new data, and titled “The AtEase Sudy: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX-102 SL* in the Treatment of Military-Related PTSD,” can be found on Tonix’s website on the Scientific Presentations page.



Dr. Sullivan commented, “The data from this sub-group analysis is very exciting and reassuring since, typically, combat-related PTSD is the most difficult to treat, and TNX-102 SL can be an important treatment option for this group based on this sub-group analysis. The retrospective analysis of the CAPS-5 ≥ 33 subset is relevant to our Phase 3 plan, because CAPS-5 ≥ 33 will be the enrollment criteria for future registration studies.”



Seth Lederman, M.D., president and chief executive officer of Tonix, added, “This combat-related PTSD sub-group analysis confirms that TNX-102 SL has the potential to improve the health and function of military veterans suffering from PTSD, including those whose trauma directly resulted from events experienced in the combat theater. We are committed to developing a treatment solution for military-related PTSD, and Tonix remains on target to initiate the first of the two 12-week, randomized, double-blind, placebo-controlled Phase 3 studies in military-related PTSD in the first quarter of 2017.”



*TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an Investigational New Drug and has not been approved for any indication.



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TNXP News